Telbivudine versus lamivudine in patients with chronic hepatitis B

Telbivudine versus lamivudine in patients with chronic hepatitis B

BACKGROUND: Reducing hepatitis B virus (HBV) replication to minimal levels is emerging as a key therapeutic goal for chronic hepatitis B. METHODS: In this double-blind, phase 3 trial, 1370 patients with chronic hepatitis B were randomly assigned to receive 600 mg of telbivudine or 100 mg of lamivudi...

وصف كامل

محفوظ في:

التفاصيل البيبلوغرافية
المؤلفون الرئيسيون:	Ching Lung Lai, Edward Gane, Yun Fan Liaw, Chao Wei Hsu, Satawat Thongsawat, Yuming Wang, Yagang Chen, E. Jenny Heathcote, Jens Rasenack, Natalie Bzowej, Nikolai V. Naoumov, Adrian M. Di Bisceglie, Stefan Zeuzem, Young Myoung Moon, Zachary Goodman, George Chao, Barbara Fielman Constance, Nathaniel A. Brown
التنسيق:	دورية
منشور في:	2018
الموضوعات:	Medicine
الوصول للمادة أونلاين:	https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=37349120537&origin=inward http://cmuir.cmu.ac.th/jspui/handle/6653943832/61227
الوسوم:	إضافة وسم لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!
المؤسسة:	Chiang Mai University

مواد مشابهة

Baseline characteristics and early on-treatment response predict the outcomes of 2 years of telbivudine treatment of chronic hepatitis B
بواسطة: Zeuzem, S., وآخرون
منشور في: (2016)

Efficacy and safety of prolonged 3-year telbivudine treatment in patients with chronic hepatitis B
بواسطة: Edward J. Gane, وآخرون
منشور في: (2018)

Efficacy and safety of continuous 4-year telbivudine treatment in patients with chronic hepatitis B
بواسطة: Y. Wang, وآخرون
منشور في: (2018)

Efficacy and safety of continuous 4-year telbivudine treatment in patients with chronic hepatitis B
بواسطة: Wang Y., وآخرون
منشور في: (2014)

Efficacy and safety of continuous 4-year telbivudine treatment in patients with chronic hepatitis B
بواسطة: Y. Wang, وآخرون
منشور في: (2018)

Efficacy and safety of prolonged 3-year telbivudine treatment in patients with chronic hepatitis B
بواسطة: Gane E., وآخرون
منشور في: (2017)

Evaluation of one-year lamivudine and telbivudine therapy on chronic hepatitis b patients: Based on biochemical, virological and fibrosis status in dr. soetomo general hospital
بواسطة: Ummi Maimunah, وآخرون
منشور في: (2019)

Evaluation of one year lamivudine and telbivudine therapy on chronic hepatitis b patient: Based on biochemical, virological and fibrosis status in dr. soetomo general hospital
بواسطة: Ummi Maimunah, وآخرون
منشور في: (2019)

Treatment of hepatitis B e antigen-positive chronic hepatitis with telbivudine or adefovir: A randomized trial
بواسطة: Chan, H.L.Y., وآخرون
منشور في: (2016)

EVALUASI PEMBERIAN TERAPI LAMIVUDIN DAN TELBIVUDIN PADA PASIEN HEPATITIS B KRONIS DI RSUD DR. SOETOMO SURABAYA PADA PERIODE TERAPI 2014 – 2015
بواسطة: Erik Geraldus Edison, NIM011511133143
منشور في: (2018)

Telbivudine plus pegylated interferon alfa-2a in a randomized study in chronic hepatitis B is associated with an unexpected high rate of peripheral neuropathy
بواسطة: Marcellin Patrick, وآخرون
منشور في: (2016)

Telbivudine: A hepatitis B-specific antiviral
بواسطة: Lim, S.G.
منشور في: (2011)

Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B
بواسطة: George K.K. Lau, وآخرون
منشور في: (2018)

Efficacy of telbivudine with conditional tenofovir intensification in patients with chronic hepatitis B: Results from the 2-year roadmap strategy
بواسطة: Teerha Piratvisuth, وآخرون
منشور في: (2018)

Pharmacokinetics of telbivudine following oral administration of escalating single and multiple doses in patients with chronic hepatitis B virus infection: Pharmacodynamic implications
بواسطة: Zhou, X.-J., وآخرون
منشور في: (2016)

Lamivudine (3-TC)
بواسطة: จิราภรณ์ อังวิทยาธร
منشور في: (2020)

Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B
بواسطة: Lau G.K.K., وآخرون
منشور في: (2014)

Renal impairment after switching from stavudine/lamivudine to tenofovir/lamivudine in NNRTI-based antiretroviral regimens
بواسطة: Weerawat Manosuthi, وآخرون
منشور في: (2018)

Developmental pharmacokinetic changes of lamivudine in infants and children
بواسطة: Adriana H. Tremoulet, وآخرون
منشور في: (2018)

Developmental pharmacokinetic changes of lamivudine in infants and children
بواسطة: Tremoulet A.H., وآخرون
منشور في: (2014)

Ragaman Genetik Gen Polimerase Virus Hepatitis B Pada Pasien Hepatitis B Kronik dengan Pengobatan Telbivudine
بواسطة: Mastutik, Gondo, وآخرون
منشور في: (2015)

Metabolic benefits of switching to tenofovir/lamivudine after long-term use of stavudine/lamivudine in NNRTI-based antiretroviral regimens: A prospective study
بواسطة: Weerawat Manosuthi, وآخرون
منشور في: (2018)

SAFETY USE OF COMBINATION TENOFOVIR-LAMIVUDINE-DOLUTEGRAVIR COMPARED WITH TENOFOVIR-LAMIVUDINE-EFAVIRENZ IN HIV PATIENTS AT IBRAHIM ADJIE COMMUNITY HEALTH CENTER BANDUNG
بواسطة: Zidan Fikri Akromy, Muhammad

EFFECTIVENESS OF TENOFOVIR-LAMIVUDIN-EFAVIRENZ (TLE) COMBINATION COMPARED TO TENOFOVIR-LAMIVUDIN- DOLUTEGRAVIR (TLD) IN HIV PATIENTS AT UPTD PUSKESMAS IBRAHIM ADJIE BANDUNG
بواسطة: Basuki

PENGARUH SIMETIDIN TERHADAP ABSORPSI LAMIVUDIN PADA KELINCI
بواسطة: Aniek Setiya Budiatin, Dra., M.Si., Apt., وآخرون
منشور في: (2005)

PENGARUH SIMETIDIN TERHADAP ABSORPSI LAMIVUDIN PADA KELINCI
بواسطة: Aniek Setiya Budiatin, Dra. M.Si., Apt, وآخرون
منشور في: (2008)

PHASE TRANSFORMATION AND PHARMACEUTICS PROFILE CHARACTERIZATION OF LAMIVUDINE PSEUDOPOLYMORPHS
بواسطة: Zhafir, Hilmy

Prophylactic lamivudine prevents hepatitis B reactivation in chemotherapy patients
بواسطة: Lim, L.L., وآخرون
منشور في: (2016)

A randomized, open-label, comparative trial of zidovudine plus lamivudine versus zidovudine plus lamivudine plus didanosine in antiretroviral-naive HIV-1-infected Thai patients
بواسطة: Chaiwat Ungsedhapand, وآخرون
منشور في: (2018)

Biowaiver monographs for immediate release solid oral dosage forms: Lamivudine
بواسطة: S. Strauch, وآخرون
منشور في: (2018)

Four years of lamivudine treatment in Chinese patients with chronic hepatitis B
بواسطة: Chang, T.-T., وآخرون
منشور في: (2016)

OPTIMIZATION OF THE PRODUCTION PROCESS OF THE LAMIVUDINE ZIDOVUDINE TABLET COMBINATION AT PT. A
بواسطة: Fathiinah Hambali, Luthfi

Response to Tenofovir Among Lamivudine-experienced Hepatitis B and HIV-coinfected Adolescents
بواسطة: Linda Aurpibul, وآخرون
منشور في: (2018)

Optimization of the strength of the efavirenz/lamivudine/abacavir fixed-dose combination for paediatric patients
بواسطة: Naïm Bouazza, وآخرون
منشور في: (2018)

Response to Tenofovir Among Lamivudine-experienced Hepatitis B and HIV-coinfected Adolescents
بواسطة: Linda Aurpibul, وآخرون
منشور في: (2018)

Optimization of the strength of the efavirenz/lamivudine/abacavir fixed-dose combination for paediatric patients
بواسطة: Naïm Bouazza, وآخرون
منشور في: (2018)

Response to Tenofovir Among Lamivudine-experienced Hepatitis B and HIV-coinfected Adolescents
بواسطة: Aurpibul L., وآخرون
منشور في: (2017)

Optimization of the strength of the efavirenz/lamivudine/abacavir fixed-dose combination for paediatric patients
بواسطة: Bouazza N., وآخرون
منشور في: (2017)

Outcome of lamivudine-resistant hepatitis B virus is generally benign except in cirrhotics
بواسطة: Dan, Y.-Y., وآخرون
منشور في: (2016)

Development and validation of an oligonucleotide ligation assay to detect lamivudine resistance in hepatitis B virus
بواسطة: Ingrid A. Beck, وآخرون
منشور في: (2018)